Neovletta 28 (Ethinylestradiol, Levonorgestrel | Lactose Monohydrate)

Ethinylestradiol, the estrogen component of Neovletta 28, suppresses the hypothalamic‑pituitary‑gonadal axis, reducing the surge of luteinising hormone that triggers ovulation. It also stabilises the endometrial lining, contributing to a less favorable environment for implantation while working synergistically with levonorgestrel.

The dosing regimen for Neovletta 28 is determined by the prescribing clinician. Typically, the product is taken once daily for 21 consecutive days followed by a 7‑day hormone‑free interval, but the exact schedule and any adjustments must be individualized by a qualified healthcare professional.

Neovletta 28 is contraindicated during pregnancy (Category X) and should be discontinued if pregnancy is confirmed. While limited data exist for breastfeeding, most guidelines advise caution; the benefits and risks should be evaluated by a healthcare provider before use in lactating women.

To order Neovletta 28, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neovletta 28 contains the standard dose combination of ethinylestradiol and levonorgestrel, a widely used progestogen. Compared with newer formulations that may use different progestins or lower estrogen doses, Neovletta 28 offers a well‑characterised efficacy and safety profile, making it a familiar choice for clinicians accustomed to traditional COC regimens.

Store Neovletta 28 at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure they are out of reach of children. Do not use tablets that appear discoloured or damaged.

Neovletta 28 is taken orally with water, preferably at the same time each day. A typical cycle consists of 21 active tablets followed by a 7‑day hormone‑free interval during which withdrawal bleeding occurs. Patients should not skip tablets and should follow the prescriber’s instructions for missed doses.

The most serious risks include venous thromboembolism, arterial clotting events such as stroke or myocardial infarction, and severe allergic reactions. Women with a history of clotting disorders, uncontrolled hypertension, smoking over age 35, or certain liver diseases should be closely monitored or avoid use altogether.

Neovletta 28 should not be used by women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or who are smokers over the age of 35. It is also contraindicated in patients with known hypersensitivity to any component of the tablet.